Company intelligence / Profile preview

Dyadic Applied BioSolutions

Jupiter, Florida, USA

Ownership: Private
Development stage: Other

Overview

First-in-human Phase 1 trial for a recombinant COVID-19 vaccine (DYAI-100) showed safety and good results in 2023; animal and human health projects ongoing; multiple input proteins (albumin, transferrin, DNase I, dairy enzymes) have reached commercial or pre-commercial scale, with revenue milestone payments and launches targeted for late 2025 and 2026.

Therapeutic areas: OtherInfectious Diseases
Modalities: Recombinant proteinMonoclonal antibodyVaccineEnzymeBiologic
Industry: Non-Drug Biotech

Partnerships

Proliant Health & BiologicalsInzymes ApSGates FoundationAcademic and pharmaceutical partners (e.g., for vaccine, antibody development)

Beyond the preview

Go deeper on Dyadic Applied BioSolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dyadic Applied BioSolutions.

Explore the full profile